Expand ATAI Menu
ATAI MENU

ATAI Latest Press Releases

-- June 25, 2026 --

AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets Globe Newswire 6:00 AM

-- May 28, 2026 --

AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations Globe Newswire 9:00 AM

-- May 27, 2026 --

AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 Globe Newswire 6:00 AM

-- May 12, 2026 --

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update Globe Newswire 8:00 AM

-- April 27, 2026 --

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research Globe Newswire 4:05 AM

-- April 22, 2026 --

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder Globe Newswire 6:00 AM

-- April 14, 2026 --

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences Globe Newswire 6:00 AM

-- April 8, 2026 --

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs Globe Newswire 6:00 AM

-- March 24, 2026 --

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst Globe Newswire 6:00 AM

-- March 17, 2026 --

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation Globe Newswire 6:00 AM

-- March 10, 2026 --

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day Globe Newswire 6:00 AM

-- March 6, 2026 --

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Globe Newswire 7:00 AM

-- March 3, 2026 --

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression Globe Newswire 7:00 AM

-- February 26, 2026 --

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder Globe Newswire 7:00 AM

-- February 20, 2026 --

AtaiBeckley To Host Virtual Investor Day on March 6, 2026 Globe Newswire 7:00 AM

-- February 19, 2026 --

AtaiBeckley Appoints Michael Faerm as Chief Financial Officer Globe Newswire 7:00 AM

-- February 17, 2026 --

AtaiBeckley To Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes